1 – 10 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
- 2018
-
Mark
3-D Image-Based Dosimetry in Radionuclide Therapy
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2016
-
Mark
Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools
(
- Contribution to journal › Scientific review
- 2012
-
Mark
Patient-Specific Whole-Body Attenuation Correction Maps from a CT System for Conjugate-View-Based Activity Quantification: Method Development and Evaluation.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
-
Mark
The accuracy of absorbed dose estimates in tumours determined by Quantitative SPECT: A Monte Carlo study.
(
- Contribution to journal › Article
-
Mark
Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies.
(
- Contribution to journal › Article
- 2010
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors
2010)(
- Chapter in Book/Report/Conference proceeding › Book chapter